Drug Discovery
This section features DDW articles on drug discovery and drug development.
Page 1 to 14 of 60 |     NEXT PAGE >
Drug discovery in the age of big data By Dr Prem Premsrirut Fall 2017
How RNA interference and CRISPR/Cas9 technologies are helping to build better mouse models and push drug discovery into a new era.

Read More

Nanomedicines - exploring the past, present and future By Professor Yvonne Perrie & Dr Euan Ramsay Fall 2017
Nanoparticles, and liposomes in particular, are growing in popularity as drug delivery vehicles for anti-cancer agents and inflammatory disease therapies, as well as forming the basis of a new class of vaccines.

Read More

How one mouse strain is revolutionising drug discovery By Dr Philip Dube Fall 2017
Inbred mice are critical tools in biomedical research and one particular strain, known as C57BL/6 (Black 6 or B6, for short), is rapidly becoming the standard model for many applications and revolutionising modern research.

Read More

Advancing the drug discovery pipeline with early stage In vitro ADME and toxicity testing. Summer 17 By Dr Maureen Bunger Summer 2017
With increasing pressures on pharmaceutical companies to develop new, effective therapeutics across the board, and keep the costs of development down, the drug discovery industry needs to ensure that its standard processes and procedures are as streamlined and effective as possible.

Read More

Raising the bar on the biologics potential. Summer 17 Dr Michael Mouradian Summer 2017
In the quest for safe, efficacious and profitable therapies, pharma research is changing. There is continued pressure to fill the drug pipeline and, at the same time, globalisation of personalised medicines is complex, expensive and requires a significant time commitment.

Read More

3D Cell Culture - A rapidly emerging technique for drug discovery. Spring 17 By Hannah Gitschier, Dr Ye Fang and Dr Richard M. Eglen Spring 2017
The past decades have witnessed significant efforts toward the development of three-dimensional (3D) cell cultures. Today, 3D cell cultures are emerging not only as a new tool in early drug discovery, but also as potential therapeutics to treat disease.

Read More

A strategic vision for 21st Century drug discovery. Winter 16/17 By Dr Wayne Bowen, Dr Giles Sanders, Dr Andreas Werdich, Dr Brian Warrington and Dr Elizabeth Farrant Winter 16/17
Delivering genuine therapeutic innovation is more challenging and complex than ever. Despite major scientific breakthroughs and technological advances leading to a greater understanding of the aetiology of diseases, it is generally accepted that the current approach to creating new small molecule therapeutics remains fundamentally inefficient.

Read More

Kinases and drug discovery: protein kinases as a validated drug target. Winter 16 By Professor Said A. Goueli Winter 16/17
The role of protein and lipid kinases in cellular physiology and normal and abnormal growth has been well appreciated and has been the focus of intensive research in both academic arenas and pharmaceutical industries. The payoff for the pharmaceutical industries has been substantial.

Read More

Translational Chemical Biology: Gap assessment for advancing drug discovery, development and precision medicine. Winter 16 By Dr Mukund Chorghade, Dr Michael Liebman, Dr Gerald Lushington, Dr Stephen Naylor and Dr Rathnam Chaguturu Winter 16/17
As yesterday’s lead molecule enters today’s clinical trial, the standard operating script seems to call for product developers and clinicians to push away the originating basic scientists, lest their lofty impractical ideals disrupt a delicate balance of strategic compromise. Indeed many scientists may not understand the competing push and pull of efficacy versus toxicity and quality versus production costs.

Read More

Ion Channels - increasingly enticing targets for drug discovery. Summer 16 by Dr Douglas Krafte and Deborah Erickson Summer 2016
Drug discovery focused on ion-channel proteins began generating great value for pharmaceutical R&D programmes more than 30 years ago, giving rise to medicines still important in the pharmacopeia for treating human disease.

Read More

Reigniting pharmaceutical innovation through holistic drug targeting. Summer 16 By Dr A Roy, Prof B Patwardhan and Dr R Chaguturu Summer 2016
Modern drug discovery approaches take too long, are too expensive, have too many clinical failures and uncertain outcomes. There are many reasons for this unsustainable business model, but primarily, the approaches are not comprehensively holistic.

Read More

Drug Discovery
Page 1 to 14 of 60 |     NEXT PAGE >